Variables | Patients with cirrhosis (n=59) | Patients with non-cirrhosis (n=148) | P value |
Characteristics | |||
Age (years) | 59.0±12.0 | 54.5±13.2 | 0.024 |
Female gender | 49 (83.1%) | 134 (90.5%) | 0.130 |
AST (IU/L) | 108 (67–279) | 262 (95–621) | <0.001 |
ALT (IU/L) | 94 (53–165) | 230 (98–640) | <0.001 |
ALP (IU/L) | 135 (96–209) | 146 (96–200) | 0.949 |
Albumin (g/dL) | 3.4±0.7 | 3.7±0.7 | 0.004 |
Globulin (g/dL) | 4.8±1.1 | 4.5±1.0 | 0.059 |
Platelet (x109/L) | 186±68 | 221±83 | 0.005 |
Haemoglobin (g/dL) | 11.6±1.7 | 12.3±1.5 | 0.003 |
INR | 1.10 (1.00–1.24) | 1.10 (1.03–1.28) | 0.344 |
Liver histology | |||
Interface hepatitis | 57 (96.6%) | 140 (94.6%) | 0.542 |
Predominantly lymphoplasmacytic infiltrate | 58 (98.3%) | 142 (95.9%) | 0.398 |
Rosette formation | 8 (13.6%) | 20 (13.5%) | 0.993 |
Biliary changes | 12 (20.3%) | 22 (14.9%) | 0.338 |
Complications of liver biopsy | |||
All adverse events | 6 (10.2%) | 6 (4.1%) | 0.090 |
Pain at the hepatic puncture site | 4 (6.8%) | 6 (4.1%) | 0.410 |
Severe pain requiring intravenous analgesics | 2 (3.4%) | 1 (0.7%) | 0.141 |
Postbiopsy bleeding | 3 (5.1%) | 0 (0%) | 0.022 |
Data presented as mean±SD, median and IQR, or number and percentage
A p<0.05 indicates statistical significance
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalised ratio